The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

R1626 Could Help Defeat Hepatitis C

Back to News Homepage

Next

Early Hepatitis C Treatment Increases Success

Popular Blood Thinner May Reduce Liver Scarring for HCV Patients

August 12, 2008

Print this page

Successful animal studies have paved the way for a human trial to determine if warfarin prevents liver damage in those with Hepatitis C.

Warfarin may prevent liver failure in hepatitis C patients

http://www.healthcarerepublic.com/news/PHARMACIST/836668/Warfarin-may
-prevent-liver-failure-hepatitis-C-patients/
05-Aug-08

Warfarin could be used to prevent liver failure in thousands of patients with hepatitis C, a new study suggests.

UK researchers found that warfarin significantly reduced the level of liver fibrosis in mice with chronic liver injury.

Digital image analysis of liver histology of wild-type mice treated with warfarin showed a 33 per cent reduction in mean fibrosis area compared with controls, according to the study published in the Journal of Thrombosis and Haemostasis.

The alpha-smooth muscle actin, which is a biochemical marker of fibrosis at a cellular level, was also reduced by 10 per cent in wild-type mice treated with warfarin.

It follows previous research by the same group which found that patients prone to blood clotting who have hepatitis C have accelerated liver scarring.

The researchers have now begun a two-year multi-centre trial, funded by the Medical Research Council (MRC), in 90 hepatitis C patients who have had liver transplants. These patients suffer rapid progression to fibrosis, and the follow-up trial should bring faster results, the researchers say.

No Comments - be the first!
Share
Share

Previous

R1626 Could Help Defeat Hepatitis C

Back to News Homepage

Next

Early Hepatitis C Treatment Increases Success

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.